| GenLei™ Scimax™ |
Filgrastim /
rhG-CSF injection |
| 75, 150, 200, 300 µg per vial |
|
| Either you are new players who want to enter into the generics business or you are eagerly searching for new products to expand your generics portfolio. Please pay great attention to our highly recommended product - Filgrastim (GenLei™ Scimax™ G-CSF). The reasons for your choosing Scimax™ filgrastim are: |
| |
Attractive market |
| |
The worldwide market for Colony Stimulating Factors was valued at $3.6 billion every year.
The market has been growing at an average annual growth rate of 16% in the previous 5 years. |
| |
Opening market for a new blockbuster generic |
| |
Amgen's Neupogen filgrastim will lose its key patent in major markets in 2006; the market is open for generics. |
| |
GenSci จC your reliable partner for generics |
| |
Please go to "About Us" to know more about GenSci. |
| |
GenLei™ Scimax™ Filgrastim- High quality with competitive prices |
| |
Please check great features below for Scimax™ filgrastim. |
|
Scimax™ filgrastim is produced by GenSci using the patented E.coli secretion expression system. Scimax™ is a highly purified preparation of recombinant human granulocyte colony stimulating factor (G-CSF) with 174 amino acid residues. The amino acid sequence of Scimax™ is identical to that of the native G-CSF produced in the human body. In contrast, Amgen's Neupogen has 175 amino acids with an extra methionin (Met-Filgrastim). rhG-CSF stimulates the production of infection-fighting white blood cells called neutrophils that are depleted by cytotoxic chemotherapy, a condition called neutropenia.
|
| กค |
The world's only rhG-CSF with 174 amino acid residues made by patented E.coli |
| |
secretion technology (patent # ZL 98 1 03011.4) |
| กค |
Biological potency higher than that of Neupogen (Met-Filgrastim by Amgen) |
| กค |
Leading G-CSF brand in China, launched in 1998 |
| กค |
Good postmarketing safety history in the market with no unexpected side effects |
|
| |
|
|
| |
|
|
กกกกกกกกกกกกกก
|
back to top